← Back to Search

Cancer Vaccine

Vaccine Therapy + Temozolomide for Glioblastoma

Phase < 1
Waitlist Available
Led By Ian Parney
Research Sponsored by Mayo Clinic
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 5 years
Awards & highlights

Study Summary

This trial is testing a new immunotherapy treatment for glioblastoma, which is a type of brain cancer.

Eligible Conditions
  • Glioblastoma
  • Gliosarcoma

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 5 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 5 years for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Incidence of significant toxicity, defined as grade 3 or higher adverse event that is possibly, probably, or definitely related to treatment measured using National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 4.0
Secondary outcome measures
Change in immunologic correlates
Clinical benefit rate
Duration of response
+2 more

Trial Design

1Treatment groups
Experimental Treatment
Group I: Treatment (vaccine therapy and temozolomide)Experimental Treatment3 Interventions
COURSE 1: Patients receive temozolomide PO daily on days 1-5. COURSES 2-3: Patients receive temozolomide PO daily on days 1-5 and malignant glioma tumor lysate-pulsed autologous dendritic cell vaccine ID on days 1, 3, and 5. COURSES 4-6: Patients receive temozolomide PO daily on days 1-5 and malignant glioma tumor lysate-pulsed autologous dendritic cell vaccine ID on day 1. COURSES 7-12: Patients receive malignant glioma tumor lysate-pulsed autologous dendritic cell vaccine ID on day 1. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Malignant Glioma Tumor Lysate-Pulsed Autologous Dendritic Cell Vaccine
2013
Completed Early Phase 1
~50
Temozolomide
2010
Completed Phase 3
~1930

Find a Location

Who is running the clinical trial?

Mayo ClinicLead Sponsor
3,205 Previous Clinical Trials
3,766,763 Total Patients Enrolled
14 Trials studying Glioblastoma
778 Patients Enrolled for Glioblastoma
National Cancer Institute (NCI)NIH
13,654 Previous Clinical Trials
40,933,132 Total Patients Enrolled
322 Trials studying Glioblastoma
23,094 Patients Enrolled for Glioblastoma
Ian ParneyPrincipal InvestigatorMayo Clinic
1 Previous Clinical Trials
20 Total Patients Enrolled
1 Trials studying Glioblastoma
20 Patients Enrolled for Glioblastoma

Media Library

Malignant Glioma Tumor Lysate-Pulsed Autologous Dendritic Cell Vaccine (Cancer Vaccine) Clinical Trial Eligibility Overview. Trial Name: NCT01957956 — Phase < 1
Glioblastoma Research Study Groups: Treatment (vaccine therapy and temozolomide)
Glioblastoma Clinical Trial 2023: Malignant Glioma Tumor Lysate-Pulsed Autologous Dendritic Cell Vaccine Highlights & Side Effects. Trial Name: NCT01957956 — Phase < 1
Malignant Glioma Tumor Lysate-Pulsed Autologous Dendritic Cell Vaccine (Cancer Vaccine) 2023 Treatment Timeline for Medical Study. Trial Name: NCT01957956 — Phase < 1

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Has this trial been previously tested in similar contexts?

"As of today, 205 distinct medical studies exploring the efficacy of Malignant Glioma Tumor Lysate-Pulsed Autologous Dendritic Cell Vaccine are active in over 36 countries and 935 cities. This technology was initially trialed by Schering-Plough with a cohort size of 60 patients back in 2002; since then, 853 trials have been completed."

Answered by AI

What type of health condition does Malignant Glioma Tumor Lysate-Pulsed Autologous Dendritic Cell Vaccine typically combat?

"Malignant Glioma Tumor Lysate-Pulsed Autologous Dendritic Cell Vaccine is primarily taken to counter the effects of nitrosourea treatment. Additionally, this medication can be beneficial for individuals with refractory advanced mycosis fungoides as well as those struggling with refractory neuroblastoma and other conditions."

Answered by AI

What findings have been identified about the efficacy of Malignant Glioma Tumor Lysate-Pulsed Autologous Dendritic Cell Vaccine in prior studies?

"Currently, 205 ongoing studies involving Malignant Glioma Tumor Lysate-Pulsed Autologous Dendritic Cell Vaccines are underway with 23 of them in Phase 3. Of the 4728 sites running these trials, Seoul and Songpa have the highest concentration."

Answered by AI

How many participants is the clinical trial accommodating at its maximum?

"This medical investigation is not presently accepting new participants. The trial opened on November 11th, 2013 and was last updated over nine years later; however, there are 442 active clinical trials for glioblastoma and 205 studies recruiting patients with Malignant Glioma Tumor Lysate-Pulsed Autologous Dendritic Cell Vaccine at this moment in time."

Answered by AI

Is there a chance to join this investigation at present?

"Regrettably, this clinical trial has ceased recruiting participants. First posted on November 11th 2013 and last edited the same day in 2022, those searching for alternatives can explore 442 trials actively enrolling patients with glioblastoma or 205 studies utilizing Malignant Glioma Tumor Lysate-Pulsed Autologous Dendritic Cell Vaccine."

Answered by AI
Recent research and studies
clinicaltrials.govStudy
Vaccine Therapy and Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma
2013. "Vaccine Therapy and Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT01957956.
~2 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top